Dabigatran etexilate (Pradaxa®) – for the prevention of stroke and systematic embolisom in atrial fibrillation

Assessment Status Assessment Process Complete
HTA ID -
Drug Dabigatran
Brand Pradaxa®
Indication For the prevention of stroke and systemic embolism in atrial fibrillation
Assessment Process
Full submission received from Applicant 02/11/2010
NCPE assessment completed 03/06/2011
NCPE assessment outcome Reimbursement not recommended

Technical Summary

03/10/2012

Following the NCPE pharmacoeconomic assessment (August 2011) the manufacturer reduced the price of dabigatran.  At this revised price we now consider dabigatran cost effective for this indication.